# 3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546

> **NCT04727138** · PHASE1 · COMPLETED · sponsor: **Exscientia AI Limited** · enrollment: 64 (actual)

## Conditions studied

- Oncology

## Interventions

- **DRUG:** EXS21546 Powder for Oral Suspension
- **DRUG:** EXS21546 Granule in Capsule
- **OTHER:** Midazolam
- **OTHER:** Food Effect
- **OTHER:** Placebo Powder for Oral Suspension

## Key facts

- **NCT ID:** NCT04727138
- **Lead sponsor:** Exscientia AI Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-08
- **Primary completion:** 2022-04-16
- **Final completion:** 2022-05-12
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2022-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04727138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04727138, "3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04727138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*